The impact of COVID-19 on liver transplantation programs in Austria.
COVID-19
Liver cirrhosis
Liver transplantation
SARS-CoV‑2
Vaccination
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
24
08
2022
accepted:
01
10
2022
pubmed:
13
11
2022
medline:
16
12
2022
entrez:
12
11
2022
Statut:
ppublish
Résumé
Coronavirus disease of 2019 (COVID-19) has affected liver disease management. The impact of the COVID-19 pandemic on the Austrian orthotopic liver transplantation (OLT) programs, however, has not been systematically investigated. All patients listed for OLT in Austria during 2020-2021 were studied. Data on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing, vaccinations, infections, mortality and the overall number of OLTs (vs. pre-COVID-19: 2015-2019) were analyzed. Overall, 490 patients (median age: 58.0 years, 70.4% men, hepatocellular carcinoma: 27.3%) were listed for OLT in Austria in 2020-2021. Alcohol-related cirrhosis (35.3%), cholestatic (16.7%) and viral liver disease (13.9%) were the main etiologies. Of the patients 61.2% underwent OLT and 8.8% died while on the waiting list. The number of OLTs performed during COVID-19 (2020: n = 150; 2021: n = 150) remained unchanged compared to pre-COVID-19 (median: n = 152). Among waiting list patients, 7.7% (n = 31/401) were diagnosed with COVID-19 and 7 (22.6%) of these patients died. By the end of 2021, 45.1% (n = 176/390; 82.8% mRNA vaccinations) and 28.8% (105/365) of patients received 2 and 3 SARS-CoV‑2 vaccinations, respectively. After two SARS-CoV‑2 vaccinations, antibodies more often remained undetectable in patients vaccinated post-OLT (25.6% vs. 6.5% in patients vaccinated pre-OLT; p = 0.034). Patients with three vaccinations after OLT had lower antibody titers than patients vaccinated pre-OLT (post-OLT: 513.5, IQR 44.4-2500.0 vs. pre-OLT: 2500.0, IQR 1462.0-2500.0 BAU/mL; p = 0.020). The number of OLTs in Austria remained unchanged during COVID-19. SARS-CoV‑2 infections were rare but associated with high mortality in patients on the Austrian OLT waiting lists. SARS-CoV‑2 vaccination rates at the end of 2021 were suboptimal, while serological response was better in patients vaccinated pre-OLT vs. post-OLT.
Sections du résumé
BACKGROUND
BACKGROUND
Coronavirus disease of 2019 (COVID-19) has affected liver disease management. The impact of the COVID-19 pandemic on the Austrian orthotopic liver transplantation (OLT) programs, however, has not been systematically investigated.
METHODS
METHODS
All patients listed for OLT in Austria during 2020-2021 were studied. Data on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing, vaccinations, infections, mortality and the overall number of OLTs (vs. pre-COVID-19: 2015-2019) were analyzed.
RESULTS
RESULTS
Overall, 490 patients (median age: 58.0 years, 70.4% men, hepatocellular carcinoma: 27.3%) were listed for OLT in Austria in 2020-2021. Alcohol-related cirrhosis (35.3%), cholestatic (16.7%) and viral liver disease (13.9%) were the main etiologies. Of the patients 61.2% underwent OLT and 8.8% died while on the waiting list. The number of OLTs performed during COVID-19 (2020: n = 150; 2021: n = 150) remained unchanged compared to pre-COVID-19 (median: n = 152). Among waiting list patients, 7.7% (n = 31/401) were diagnosed with COVID-19 and 7 (22.6%) of these patients died. By the end of 2021, 45.1% (n = 176/390; 82.8% mRNA vaccinations) and 28.8% (105/365) of patients received 2 and 3 SARS-CoV‑2 vaccinations, respectively. After two SARS-CoV‑2 vaccinations, antibodies more often remained undetectable in patients vaccinated post-OLT (25.6% vs. 6.5% in patients vaccinated pre-OLT; p = 0.034). Patients with three vaccinations after OLT had lower antibody titers than patients vaccinated pre-OLT (post-OLT: 513.5, IQR 44.4-2500.0 vs. pre-OLT: 2500.0, IQR 1462.0-2500.0 BAU/mL; p = 0.020).
CONCLUSION
CONCLUSIONS
The number of OLTs in Austria remained unchanged during COVID-19. SARS-CoV‑2 infections were rare but associated with high mortality in patients on the Austrian OLT waiting lists. SARS-CoV‑2 vaccination rates at the end of 2021 were suboptimal, while serological response was better in patients vaccinated pre-OLT vs. post-OLT.
Identifiants
pubmed: 36369363
doi: 10.1007/s00508-022-02105-z
pii: 10.1007/s00508-022-02105-z
pmc: PMC9651874
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
875-882Subventions
Organisme : Medical Scientific Fund of the Mayor of the City of Vienna
ID : MA 40-GMWF-485569-2020
Informations de copyright
© 2022. The Author(s).
Références
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
doi: 10.1016/S0140-6736(20)30183-5
Atzrodt CL, Maknojia I, McCarthy RDP, Oldfield TM, Po J, Ta KTL, et al. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV‑2. FEBS J. 2020;287(17):3633–50.
doi: 10.1111/febs.15375
Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020;55(5):105951.
doi: 10.1016/j.ijantimicag.2020.105951
Hartl L, Haslinger K, Angerer M, Jachs M, Simbrunner B, Bauer DJM, et al. Age-adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID-19 patients. Liver Int. 2022;42(6):1297–307.
doi: 10.1111/liv.15274
Hartl L, Semmler G, Hofer BS, Schirwani N, Jachs M, Simbrunner B, et al. COVID-19-related downscaling of in-hospital liver care decreased patient satisfaction and increased liver-related mortality. Hepatol Comm. 2021;5(10):1660–75.
doi: 10.1002/hep4.1758
Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2(3):100113.
doi: 10.1016/j.jhepr.2020.100113
Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, et al. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Rep. 2020;2(5):100169.
doi: 10.1016/j.jhepr.2020.100169
Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV‑2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973–87.
doi: 10.1016/S0140-6736(20)31142-9
Lai CC, Wang CY, Wang YH, Hsueh SC, Ko WC, Hsueh PR. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020;55(4):105946.
doi: 10.1016/j.ijantimicag.2020.105946
Iavarone M, D’Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020;73(5):1063–71.
doi: 10.1016/j.jhep.2020.06.001
Moon AM, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasekaran R, et al. High mortality rates for SARS-CoV‑2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. J Hepatol. 2020;73(3):705–8.
doi: 10.1016/j.jhep.2020.05.013
Singh S, Khan A. Clinical characteristics and outcomes of Coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study. Gastroenterology. 2020;159(2):768–771.e3.
doi: 10.1053/j.gastro.2020.04.064
Hartl L, Jachs M, Simbrunner B, Bauer DJM, Semmler G, Gompelmann D, et al. Cirrhosis-associated RAS-inflammation-coagulation axis anomalies: parallels to severe COVID-19. J Pers Med. 2021;11(12):1264. https://doi.org/10.3390/jpm11121264 .
doi: 10.3390/jpm11121264
Hartl L, Haslinger K, Angerer M, Semmler G, Schneeweiss-Gleixner M, Jachs M, et al. Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in chronic liver disease patients. Hepatology. 2022;10.1002/hep.32582. https://doi.org/10.1002/hep.32582 .
doi: 10.1002/hep.32582
Marjot T, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, et al. Outcomes following SARS-CoV‑2 infection in patients with chronic liver disease: An international registry study. J Hepatol. 2021;74(3):567–77.
doi: 10.1016/j.jhep.2020.09.024
Dumortier J, Duvoux C, Roux O, Altieri M, Barraud H, Besch C, et al. Covid-19 in liver transplant recipients: the French SOT COVID registry. Clin Res Hepatol Gastroenterol. 2021;45(4):101639.
doi: 10.1016/j.clinre.2021.101639
Hadi YB, Naqvi SFZ, Kupec JT, Sofka S, Sarwari A. Outcomes of COVID-19 in solid organ transplant recipients: a propensity-matched analysis of a large research network. Transplantation. 2021;105(6):1365–71.
doi: 10.1097/TP.0000000000003670
Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: aASLD expert panel consensus statement. Hepatology. 2020;72(1):287–304.
doi: 10.1002/hep.31281
Tapper EB, Asrani SK. The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. J Hepatol. 2020;73(2):441–5.
doi: 10.1016/j.jhep.2020.04.005
Pawlotsky JM. COVID-19 and the liver-related deaths to come. Nat Rev Gastroenterol Hepatol. 2020;17(9):523–5.
doi: 10.1038/s41575-020-0328-2
Di Maira T, Berenguer M. COVID-19 and liver transplantation. Nat Rev Gastroenterol Hepatol. 2020;17(9):526–8.
doi: 10.1038/s41575-020-0347-z
Boyarsky BJ, Chiang P‑YT, Werbel WA, Durand CM, Avery RK, Getsin SN, et al. Early impact of COVID-19 on transplant center practices and policies in the United States. Am J Transplant. 2020;20(7):1809–18.
doi: 10.1111/ajt.15915
Angelico R, Trapani S, Manzia TM, Lombardini L, Tisone G, Cardillo M. The COVID-19 outbreak in Italy: Initial implications for organ transplantation programs. Am J Transplant. 2020;20(7):1780–4.
doi: 10.1111/ajt.15904
Russo FP, Izzy M, Rammohan A, Kirchner VA, Di Maira T, Belli LS, et al. Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS). J Hepatol. 2022;76(2):364–70.
doi: 10.1016/j.jhep.2021.09.041
Nobel YR, Phipps M, Verna EC. COVID-19 and effect on liver transplant. Curr Treat Options Gastroenterol. 2021;19(3):483–99.
doi: 10.1007/s11938-021-00355-w
Bittermann T, Mahmud N, Abt P. Trends in liver transplantation for acute alcohol-associated hepatitis during the COVID-19 pandemic in the US. JAMA Netw Open. 2021;4(7):e2118713.
doi: 10.1001/jamanetworkopen.2021.18713
Cholankeril G, Goli K, Rana A, Hernaez R, Podboy A, Jalal P, et al. Impact of COVID-19 pandemic on liver transplantation and alcohol-associated liver disease in the USA. Hepatology. 2021;74(6):3316–29.
doi: 10.1002/hep.32067
Thuluvath PJ, Robarts P, Chauhan M. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. J Hepatol. 2021;75(6):1434–9.
doi: 10.1016/j.jhep.2021.08.008
Rabinowich L, Grupper A, Baruch R, Ben-Yehoyada M, Halperin T, Turner D, et al. Low immunogenicity to SARS-CoV‑2 vaccination among liver transplant recipients. J Hepatol. 2021;75(2):435–8.
doi: 10.1016/j.jhep.2021.04.020
WHO. Diagnostic testing for SARS-CoV‑2. 2020. https://www.who.int/publications/i/item/diagnostic-testing-for-sars-cov-2 . Accessed 29 Apr 2022.
Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R, et al. Anti-spike protein assays to determine SARS-coV‑2 antibody levels: a head-to-head comparison of five quantitative assays. Microbiol Spectr. 2021;9(1):e24721.
doi: 10.1128/Spectrum.00247-21
Higgins V, Fabros A, Kulasingam V. Quantitative measurement of anti-SARS-coV‑2 antibodies: analytical and clinical evaluation. J Clin Microbiol. 2021;59(4):e03149–20. https://doi.org/10.1128/JCM.03149-20 .
doi: 10.1128/JCM.03149-20
Mrak D, Sieghart D, Simader E, Tobudic S, Radner H, Mandl P, et al. Heterologous versus homologous booster vaccination in non-seroconverted immunosuppressed patients after primary mRNA vaccination: a randomized controlled trial. unpublished. 2022.
Eurotransplant International Foundation. Annual Report 2021. 2022. https://www.eurotransplant.org/wp-content/uploads/2022/06/Annual-Report-2021_LR.pdf . Accessed 21 July 2022.
Lembach H, Hann A, McKay SC, Hartog H, Vasanth S, El-Dalil P, et al. Resuming liver transplantation amid the COVID-19 pandemic. Lancet Gastroenterol Hepatol. 2020;5(8):725–6.
doi: 10.1016/S2468-1253(20)30187-4
Danziger-Isakov L, Blumberg EA, Manuel O, Sester M. Impact of COVID-19 in solid organ transplant recipients. Am J Transplant. 2021;21(3):925–37.
doi: 10.1111/ajt.16449
ÖGGH. Informationen für immunsupprimierte PatientInnen nach Lebertransplantation anlässlich der Pandemie mit dem neuen Coronavirus SARS-CoV‑2. 2020. http://www.oeggh.at/files/info_patientinnen_lebertransplantation_coronavirus_sars-cov-2.pdf . Accessed 16 May 2022.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.
doi: 10.1056/NEJMoa2034577
Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and immunogenicity of SARS-coV‑2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427–38.
doi: 10.1056/NEJMoa2028436
Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979–93.
doi: 10.1016/S0140-6736(20)32466-1
ÖGGH. Update der ÖGGH Stellungnahme zur COVID-19 Impfung bei Lebererkrankungen und unter Immunsuppression nach Lebertransplantation. 2021. http://www.oeggh.at/files/oeggh_leber_covid_impfung_statement_21.02.24.pdf . Accessed 16 May 2022.